Peer-influenced content. Sources you trust. No registration required. This is HCN.
First Report Managed Care
In an era where specialty drug costs soar, Alternative Funding Programs present a complex solution, balancing cost containment with patient access to essential medications. These programs, while offering potential savings, may also introduce treatment delays and increased financial burdens for patients.
All Specialties March 11th 2024
Pharmacy Today
The study’s findings underscore the importance of addressing the high cost of insulin. Despite new products and discounts entering the market, one in four patients still report cost as a barrier to accessing their necessary insulin.
Clinical Pharmacology October 30th 2023
The New England Journal of Medicine
Discover how the Inflation Reduction Act influences pharmaceutical innovation and drug pricing. Learn why delaying drug launches might not be an optimal strategy.
Hematology/Oncology October 17th 2023
Oncology News Central (ONC)
Discover how a recent class-action lawsuit against Bristol Myers Squibb could impact the availability and cost of multiple myeloma treatment options.
Hematology/Oncology September 11th 2023
Clinical Oncology News
Discover how the 340B Drug Pricing Program influences prescription trends toward higher-cost biologics over biosimilars, and what this means for cost-effective healthcare.
Clinical Pharmacology September 5th 2023
New research underscores the dramatic increase in prior authorization for oral oncology drugs under Medicare Part D. Understand the implications for your practice as insurers tighten their grip on treatment decisions.
Hematology/Oncology September 5th 2023